A Phase 4 interventional study of Intranasal corticosteroids (INCS) combined with oral antihistamines (OAH) used for treatment and Intranasal corticosteroids (INCS) combined with nasal antihistamines (INAH) used for treatment. in Allergic Rhinitis, sponsored by China-Japan Union Hospital. Not yet recruiting. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by China-Japan Union Hospital · Phase 4, Interventional, and Treatment
Through prospective exploration of the efficacy of intranasal corticosteroids (INCS) combined with intranasal antihistamines (INAH) and INCS combined with oral antihistamines (OAH) in treating moderate to severe allergic rhinitis symptoms, this study aims to provide evidence-based medical evidence for the standardized treatment of patients with moderate to severe allergic rhinitis accompanied by typical nasal and ocular symptoms.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
This study's planned enrollment of 50 is below the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Browse Rhinitis, Allergic studies →China-Japan Union Hospital is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intranasal corticosteroids (INCS) combined with oral antihistamines (OAH) used for treatment. Fluticasone propionate nasal spray (Fushuliang) combined with Azlastine hydrochloride tablets (Kedumin), Fluticasone propionate nasal spray (Fushuliang) 1 spray (50 µ g Fluticasone propionate) on each side of the nostril, twice a day, and Azlastine hydrochloride tablets (Kedumin) 2mg once a day, twice a day, once an hour before breakfast, once at night before sleep, for 14 consecutive days.
Drug: Intranasal corticosteroids (INCS) combined with oral antihistamines (OAH) used for treatment
Intranasal corticosteroids (INCS) combined with nasal antihistamines (INAH) used for treatment. Azolastine and fluticasone nasal spray (Demins) were selected, and one spray (137 µ g Azolastine Hydrochloride and 50 µ g Fluticasone Propionate) was applied to each nostril twice a day for 14 consecutive days.
Drug: Intranasal corticosteroids (INCS) combined with nasal antihistamines (INAH) used for treatment.
Intranasal corticosteroids (INCS) combined with oral antihistamines (OAH) used for treatment. Fluticasone propionate nasal spray (Fushuliang) combined with Azlastine hydrochloride tablets (Kedumin), Fluticasone propionate nasal spray (Fushuliang) 1 spray (50 µ g Fluticasone propionate) on each side of the nostril, twice a day, and Azlastine hydrochloride tablets (Kedumin) 2mg once a day, twice a day, once an hour before breakfast, once at night before sleep, for 14 consecutive days.
Intranasal corticosteroids (INCS) combined with nasal antihistamines (INAH) used for treatment. Azolastine and fluticasone nasal spray (Demins) were selected, and one spray (137 µ g Azolastine Hydrochloride and 50 µ g Fluticasone Propionate) was applied to each nostril twice a day for 14 consecutive days.
Total Nasal Symptom Score (TNSS)
Description: The minimum possible scale value is 0, and the maximum possible scale value is 12. The higher scores mean a worse outcome.
Time frame: Before the start of treatment, on the 3rd, 7th, and 14th day of treatment
Total Ocular Symptom Score (TOSS)
The minimum possible scale value is 0, and the maximum possible scale value is 9. The higher scores mean a worse outcome.
Time frame: Before the start of treatment, on the 3rd, 7th, and 14th day of treatment
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
The minimum possible scale value is 0, and the maximum possible scale value is 168. The higher scores mean a worse outcome.
Time frame: Before the start of treatment, on the 3rd, 7th, and 14th day of treatment
General Health Status Score (SF36)
The general health status score of patients is evaluated in nine dimensions: physiological function (PF), physiological function (RP), physical pain (BP), general health status (GH), energy (VT), social function (SF), emotional function (RE), mental health (MH), and health change (HT). Scores for each dimension range from 0 to 100, with higher scores indicating higher quality of life
Time frame: Before the start of treatment, on the 3rd, 7th, and 14th day of treatment
Endoscopic sinus scoring (Lund-Kennedy)
Time frame: Before the start of treatment, the 14th day of treatment
blood cell count
Time frame: Before the start of treatment, the 14th day of treatment
serum IgE level
Time frame: Before the start of treatment, the 14th day of treatment
nasal secretions IgE level
Time frame: Before the start of treatment, the 14th day of treatment
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China-Japan Union Hospital